Marksans Pharma Limited (NSE: MARKSANS)

Market Cap	139.87B
Revenue (ttm)	23.79B
Net Income (ttm)	3.47B
Shares Out	453.16M
EPS (ttm)	7.65
PE Ratio	40.35
Forward PE	31.52
Dividend	0.60 (0.19%)
Ex-Dividend Date	Sep 17, 2024

Volume	2,944,586
Open	310.00
Previous Close	309.15
Day's Range	306.05 - 319.20
52-Week Range	130.00 - 328.80
Beta	1.65
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Marksans Pharma

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamin...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 1,141
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MARKSANS

Financial Performance

In 2023, Marksans Pharma's revenue was 21.77 billion, an increase of 17.56% compared to the previous year's 18.52 billion. Earnings were 3.14 billion, an increase of 17.80%.